Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

OBJECTIVES: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Xiaomei, Lin, Wei, Liu, Shixue, Kanik, Keith, Wang, Cunshan, Wan, Weiguo, Jiang, Zhenyu, Liu, Yi, Liu, Shengyun, Zhang, Zhuoli, Zhang, Zhiyi, Xu, Jian, Tan, Wenfeng, Hu, Jiankang, Li, Jingyang, Liu, Ju, Gunay, Levent M., Dina, Oluwaseyi, Kinch, Cassandra, Zeng, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890804/
https://www.ncbi.nlm.nih.gov/pubmed/36720560
http://dx.doi.org/10.1136/rmdopen-2022-002559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890804/
https://www.ncbi.nlm.nih.gov/pubmed/36720560
http://dx.doi.org/10.1136/rmdopen-2022-002559

Ejemplares similares